Establishment Labs (NASDAQ:ESTA – Get Free Report) and Basel Medical Group (NASDAQ:BMGL – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.
Profitability
This table compares Establishment Labs and Basel Medical Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Establishment Labs | -43.45% | -235.45% | -22.83% |
| Basel Medical Group | N/A | N/A | N/A |
Valuation and Earnings
This table compares Establishment Labs and Basel Medical Group”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Establishment Labs | $166.02 million | 11.93 | -$84.60 million | ($2.84) | -24.00 |
| Basel Medical Group | $8.90 million | 1.51 | -$9.50 million | N/A | N/A |
Basel Medical Group has lower revenue, but higher earnings than Establishment Labs.
Institutional and Insider Ownership
72.9% of Establishment Labs shares are owned by institutional investors. 11.1% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Establishment Labs and Basel Medical Group, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Establishment Labs | 1 | 1 | 6 | 0 | 2.63 |
| Basel Medical Group | 1 | 0 | 0 | 0 | 1.00 |
Establishment Labs presently has a consensus price target of $78.86, indicating a potential upside of 15.71%. Given Establishment Labs’ stronger consensus rating and higher possible upside, equities analysts plainly believe Establishment Labs is more favorable than Basel Medical Group.
Summary
Establishment Labs beats Basel Medical Group on 7 of the 11 factors compared between the two stocks.
About Establishment Labs
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
About Basel Medical Group
Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.
